APOA1 and amyotrophic lateral sclerosis: In conclusion, our study provided new evidence supporting the benefits of systemically administered ApoA1 in ALS mice of both genders at the early symptomatic disease stage, likely due to restorative effects on damaged microvessels, toward repair of the blood–spinal cord barrier.